Although urinary Bcl-2 looks promising with an AUC of 0.90 reported in the validation cohort, this biomarker is not specific to ovarian cancer as it is also over-expressed in lymphoma, colorectal and lung cancer, and is therefore unlikely to be useful in clinical practice (19). The gene discussed is BCL2; the disease is lymphoma.